{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:49:10Z","timestamp":1775908150203,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,18]]},"DOI":"10.7759\/cureus.18085","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T21:28:30Z","timestamp":1632000510000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis"],"prefix":"10.7759","author":[{"given":"Jaffar","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terrence","family":"Katona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2017.112","article-title":"Checkpoint inhibitor-induced colitis: a new type of inflammatory bowel disease?","volume":"4","author":"Bertha M","year":"2017","unstructured":"Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint inhibitor-induced colitis: a new type of inflammatory bowel disease?. ACG Case Rep J. 2017, 4:e112. 10.14309\/crj.2017.112","journal-title":"ACG Case Rep J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"30","author":"Robert C","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al.. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011, 30:2517-26. 10.1056\/NEJMoa1104621","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"21","author":"Mellman I","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011, 21:480-9. 10.1038\/nature10673","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat S","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al.. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016, 27:559-74. 10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2017.05.032","article-title":"Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer. (Article in French)","volume":"46","author":"Jacquin-Porretaz C","year":"2017","unstructured":"Jacquin-Porretaz C, Nardin C, Puzenat E, et al.. Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer. (Article in French). Presse Med. 2017, 46:808-17. 10.1016\/j.lpm.2017.05.032","journal-title":"Presse Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan N","year":"2018","unstructured":"Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018, 472:125-33. 10.1007\/s00428-017-2267-z","journal-title":"Virchows Arch"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-017-0540-6","article-title":"Gastrointestinal and hepatic complications of immune checkpoint inhibitors","volume":"19","author":"Cramer P","year":"2017","unstructured":"Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017, 19:3. 10.1007\/s11894-017-0540-6","journal-title":"Curr Gastroenterol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000252","article-title":"Anti-PD1-induced collagenous colitis in a melanoma patient","volume":"26","author":"Baroudjian B","year":"2016","unstructured":"Baroudjian B, Lourenco N, Pag\u00e8s C, et al.. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016, 26:308-11. 10.1097\/CMR.0000000000000252","journal-title":"Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"1","author":"Coutzac C","year":"2017","unstructured":"Coutzac C, Adam J, Soularue E, et al.. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohns Colitis. 2017, 1:1238-46. 10.1093\/ecco-jcc\/jjx081","journal-title":"J Crohns Colitis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"13","author":"Geukes Foppen MH","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, et al.. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018, 13:000278. 10.1136\/esmoopen-2017-000278","journal-title":"ESMO Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan M","year":"2017","unstructured":"Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol. 2017, 8:1547. 10.3389\/fimmu.2017.01547","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000452403","article-title":"Ipilimumab-induced enteritis without colitis: a new challenge","volume":"8","author":"Messmer M","year":"2016","unstructured":"Messmer M, Upreti S, Tarabishy Y, et al.. Ipilimumab-induced enteritis without colitis: a new challenge. Case Rep Oncol. 2016, 8:705-13. 10.1159\/000452403","journal-title":"Case Rep Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih H","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018, 6:95. 10.1186\/s40425-018-0411-1","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson DH","year":"2018","unstructured":"Johnson DH, Zobniw CM, Trinh VA, et al.. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018, 6:103. 10.1186\/s40425-018-0412-0","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/71824-immune-checkpoint-inhibitor-induced-colitis-presenting-as-lymphocytic-colitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:42Z","timestamp":1707506982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/71824-immune-checkpoint-inhibitor-induced-colitis-presenting-as-lymphocytic-colitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.18085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,18]]}}}